lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
Intra-Cellular Therapies Inc, USA.
Maastricht University, The Netherlands.
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.ORCID iD: 0000-0003-1806-307X
Intra-Cellular Therapies Inc, USA.
Show others and affiliations
2016 (English)In: Psychopharmacology, ISSN 0033-3158, E-ISSN 1432-2072, Vol. 233, no 17, 3113-3124 p.Article in journal (Refereed) Published
Abstract [en]

Rationale: Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed.

Objective: The aim of this study is to characterize the preclinical profile of ITI-214, a potent inhibitor of phosphodiesterase 1 (PDE1).

Methods: ITI-214 was assayed for inhibition of PDE1 versus other PDE enzyme families using recombinant human PDE enzymes and for off-target binding to 70 substrates (General SEP II diversity panel; Caliper Life Sciences). Effects of ITI-214 (0.1–10 mg/kg, po) on memory performance were assayed in rats using the novel object recognition (NOR) paradigm, with drug given at specified time points prior to or following exposure to objects in an open field. ITI-214 was evaluated for potential drug-drug interaction with risperidone in rats using conditioned avoidance response (CAR) and pharmacokinetic assessments.

Results: ITI-214 inhibited PDE1A (Ki = 33 pmol) with >1000-fold selectivity for the nearest other PDE family (PDE4D) and displayed minimal off-target binding interactions in a 70-substrate selectivity profile. By using specific timing of oral ITI-214 administration, it was demonstrated in the NOR that ITI-214 is able to enhance acquisition, consolidation, and retrieval memory processes. All memory effects were in the absence of effects on exploratory behavior. ITI-214 did not disrupt the risperidone pharmacokinetic profile or effects in CAR.

Conclusions: ITI-214 improved the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0.1–10 mg/kg, po) without disrupting the antipsychotic-like activity of a clinical antipsychotic medication, specifically risperidone. Clinical development of ITI-214 is currently in progress.

Place, publisher, year, edition, pages
2016. Vol. 233, no 17, 3113-3124 p.
Keyword [en]
Conditioned avoidance response, Cyclic AMP, Cyclic GMP, Memory, Novel object recognition, Phosphodiesterase-1
National Category
Pharmaceutical Sciences Pharmacology and Toxicology
Research subject
Biomedical Sciences, Pharmacology
Identifiers
URN: urn:nbn:se:lnu:diva-56076DOI: 10.1007/s00213-016-4346-2ISI: 000381586500005PubMedID: 27342643Scopus ID: 2-s2.0-84976276833OAI: oai:DiVA.org:lnu-56076DiVA: diva2:971432
Available from: 2016-09-16 Created: 2016-08-31 Last updated: 2017-02-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopusFulltext (read only)

Search in DiVA

By author/editor
Wadenberg, Marie-Louise
By organisation
Department of Chemistry and Biomedical Sciences
In the same journal
Psychopharmacology
Pharmaceutical SciencesPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf